3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
55
Neoplasm Metastasis
17
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasms
14
Pancreatic Neoplasms
11
Uveal Melanoma
10
Prostatic Neoplasms
10
Leukemia, Myeloid, Acute
9
Squamous Cell Carcinoma of Head and Neck
7
Sarcoma
7
Myelodysplastic Syndromes
7
Lymphoma
7
Lung Neoplasms
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Recurrence
5
Myeloproliferative Disorders
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Hematologic Neoplasms
5
Glioblastoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Interventions
Doxorubicin
3
pembrolizumab
2
Radiotherapy
2
ribociclib
1
peposertib
1
montanide ISA 51
1
liposomal doxorubicin
1
itacitinib
1
futibatinib
1
cixutumumab
1
belinostat
1
baricitinib
1
avelumab
1
Specimen Handling
1
Radiation
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Interleukin-2
1
Ifosfamide
1
INCB039110
1
Histamine H2 Antagonists
1
Fluorouracil
1
Famotidine
1
Erlotinib Hydrochloride
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Biopsy
1
BO-112
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Histiocytoma, Malignant Fibrous
×
Ipilimumab
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled